



Review

Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review



Erik E.L. Jansen ^{a,*}, Nadine Zielonke ^a, Andrea Gini ^a, Ahti Anttila ^b, Nereo Segnan ^c, Zoltán Vokó ^{d,e}, Urška Ivanuš ^f, Martin McKee ^g, Harry J. de Koning ^a, Inge M.C.M. de Kok ^a on behalf of the EU-TOPIA consortium¹

^a Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

^b Finnish Cancer Registry, Helsinki, Finland

^c Department of Cancer Epidemiology, CPO Piemonte, City of Health and Science University Hospital, Turin, Italy

^d Department of Health Policy & Health Economics, Eötvös Loránd University, Budapest, Hungary

^e Syreon Research Institute, Budapest, Hungary

^f Institute of Oncology Ljubljana, Ljubljana, Slovenia

^g London School of Hygiene and Tropical Medicine, London, England, UK

Received 11 November 2019; accepted 2 December 2019

Available online 21 January 2020

KEYWORDS

Uterine cervical neoplasms;
Early detection of cancer;
Mortality;
Europe;
Systematic review

Abstract Background: Organised cervical cancer (CC) screening programmes are delivered in many different ways across the European Union and its regions. Our aim was to systematically review the impact of these programs on CC mortality.

Methods: Two independent reviewers identified all eligible studies investigating the effect of organised screening on CC mortality in Europe. Six databases including Embase, Medline and Web of Science were searched (March 2018) with predefined inclusion and exclusion criteria. Only original studies with at least five years of follow-up were considered. Validated tools were used to assess the risk of bias of the included studies.

Results: Ten observational studies were included: seven cohort and three case-control studies. No randomised controlled trials were found, and there were no eligible studies from the eastern and southern part of Europe. Among the eligible studies, seven were conducted in the twentieth century; they scored lower on the risk of bias assessment. CC mortality reduction for women attending organised screening vs. non-attenders ranged from 41% to 92% in seven studies. Reductions were similar in Western (45–92%) and Northern (41–87%) Europe and

* Corresponding author: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, the Netherlands.

E-mail address: e.e.l.jansen@erasmusmc.nl (E.E.L. Jansen).

¹ Members in the collaboration group "EU-TOPIA consortium" are listed in appendix section.

were higher in the three more recent studies (66–92%). For invited vs. non-invited women, this reduction ranged from 17% to 79% in five studies.

Conclusion: Although data were lacking in Southern and Eastern Europe and the effect size varied between countries and studies, this systematic review provides evidence that organised CC screening reduces CC mortality in those parts of Europe where CC screening was implemented and monitored.

© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Cervical screening has been shown to reduce the incidence and mortality of cervical cancer (CC). Precancerous lesions can be treated, preventing progression to invasive disease [1–6], thereby avoiding the need for chemotherapy or radiotherapy or infertility due to removal of the cervix [7–9]. Screening is estimated to reduce the incidence rate of CC by 50–60% [10]. Yet although most European countries have offered some sort of CC screening for decades [11], 34,000 new CC cases are detected in Europe each year, with 13,000 deaths [12].

CC screening is most effective where it is undertaken within an organised programme. Yet, so far, 19 of the 28 countries of the European Union have yet to implement such programmes despite clear recommendations agreed by the European Council [13–15]. These recommendations advocate starting screening at an age between 20 and 30, repeating at three to five year intervals until the age of 60 or 65 [16,17]. Screening can be performed using a Pap smear to detect any abnormal cells (cytology) and/or a test to check for the presence of the human papilloma virus (HPV), the causal agent in CC [17,18]. While ten countries are currently rolling out an organised CC screening programme and three countries are currently planning or piloting such programme, six countries only have a non-population-based programme or no programme at all [13,14].

The reduction in mortality that can be achieved by a screening programme depends on several factors. These include the epidemiology of HPV infection in the population and characteristics of the screening programme, including the starting and stopping ages, screening interval and coverage [19]. Other factors include the performance of screening activities, in terms of sensitivity and specificity, access to treatment by those in whom lesions are detected and quality of follow-up. These parameters can vary widely so it is likely that observed reductions in CC mortality will also vary. However, the extent to which screening does achieve reductions in Europe, including differences among countries and over time, has not previously been brought together systematically.

This systematic review is part of the EU-TOPIA (TOwards imPROved screening for breast, cervical and colorectal cancer In All of Europe) project that is evaluating and quantifying the harms and benefits of cancer

screening in European countries, to improve health outcomes and increase equity. Both women and policymakers should know whether their screening programmes are performing optimally and the scale of the benefit that they can expect. This review seeks to address this question by searching for the best quality published evidence on the effect of screening on reducing CC mortality in the European region. This can be used to benchmark progress in countries with existing screening programmes and those that are starting new ones.

2. Methods

The systematic review was part of a large one on cancer mortality reduction associated with screening for breast, colorectal and CC within the EU-TOPIA project. The protocol of this systematic review was published in PROSPERO (International Prospective Register of Systematic Reviews, CRD42016042433) on July 6, 2016 [20]. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement served as a guideline for the performance of this systematic review [21].

2.1. Search strategy

The PICOS (population, intervention, control, outcome and study design) criteria (Table 1) from the study protocol [20] formed the basis of the search strategy in six electronic databases. Embase, Ovid Medline, Web of Science, PubMed, Google Scholar and the Cochrane Library were searched from inception until March 2018 for articles in English related to population-based CC screening and effects on CC mortality in European countries using a computer-assisted search code compiled by a research librarian (appendix Table A). Experts from the field were invited to suggest additional relevant articles and grey literature to be added to the list of potentially eligible articles. We also manually searched reference lists of pertinent articles to find any relevant citations that our searches might have missed. Duplicates were removed, and the remaining references were managed using Thomson Reuters Endnote X7.5.

2.2. Study selection

All retrieved references were screened for title and abstract by two investigators (E.J. and N.Z.)

Table 1
PICOS criteria used to include/exclude studies during the study selection process.

Parameter	Inclusion criteria	Exclusion criteria
Population	People invited to/participating in organised mass screening for cervical cancer in a European country.	People from non-European countries.
Intervention	Organised screening for cervical cancer.	Other screening interventions (e.g. opportunistic screening).
Control	People not invited to/not attending organised screening or people participating in opportunistic screening only.	Control group receiving a different type of screening (e.g. comparing cytology with HPV screening).
Outcome	Change in cervical cancer mortality due to cervical cancer screening.	No direct estimation of cervical cancer mortality reduction due to screening.
Study design	Randomised control trials, retrospective and prospective observational (cohort or case-control) studies.	Non-original research studies (e.g. editorials, letters and conference abstracts), modeling/simulation studies, ecological studies, systematic reviews and meta-analyses. Follow-up < 5 years.

PICOS, population, intervention, control, outcome and study design; HPV, human papilloma virus.

independently. Articles were selected for full-text review based on the eligibility criteria listed in Table 1. Following the IARC Handbook of Cancer Prevention [22], we defined organised screening as that within a programme organised at national or regional level based on an explicit policy. Where only incidence reduction was reported in the abstract, the article was included for full-text review to ascertain whether CC mortality reduction was reported elsewhere in the article. Discrepancies were resolved by consensus or by consulting a third investigator (A.G.) for a final judgement.

Initially, included articles were subjected to a full-text review using additional exclusion criteria inspired by Elmunzer et al. [23] Briefly, articles were excluded if (1) the study did not assess the direct effect of organised CC screening on CC mortality, (2) the study assessed test performance rather than the effect at population level, (3) the study did not present original data (information was duplicated in other articles), (4) the follow-up period was less than five years, (5) the study neither reported the number of events (in both intervention and control groups where appropriate) nor presented an outcome measure based on the relative risk (RR), rate ratio, odds ratio (OR) or percentage reduction.

2.3. Data extraction and risk of bias assessment

Data were extracted from the final list of included studies on first author, year of publication, country of the study, study design, organisation of screening implementation (regional or national), study group sizes, whether the control group was drawn from the same population as the intervention group, number of events, adherence to the intervention, follow-up time, target ages of the intervention, screening interval, all outcome measures regarding CC mortality reduction including reported 95% confidence intervals (CIs) and a note if this outcome measure was corrected for self-selection bias (healthy individuals are more likely to attend screening). The presence of conflict of interest statements and/or funding source from all included studies was also extracted. All relevant outcome

measures are presented in a table, sorted by European region as defined by the EuroVoc multilingual thesaurus of the European Union [24].

When comparing reductions in CC mortality across studies, odds ratios were interpreted as being RRs as these will be very similar as long as the incidence of the event is less than 10% in the overall population [25]. This also applies to case-control studies [26].

To assess the risk of bias of included studies, two investigators independently scored the risk of bias using the Newcastle-Ottawa Scale (NOS) for observational studies, covering the domains of study group selection, comparability between the study groups, outcome measurement and exposure to the intervention [27]. Because of the differences in the study design between cohort studies and case-control studies, different types of biases could occur so the NOS applies different questions to each [27]. A higher score on the NOS corresponds to less risk of bias. The NOS initially did not award a point for adequate case definition of case-control studies if this was based on record linkage only. Anttila et al. [28] advocated that cancer registries, when mandated and resourced, should take co-responsibility in the evaluation of the quality and impact of organised screening. In addition, as cancer registries in some countries have a very high percentage of histologically verified cases, which we designated as independent validation, we did award a point for this if the percentage was known to be more than 95% according to the International Agency for Research on Cancer [29]. All scoring discrepancies between reviewers were discussed until consensus was reached. Final decisions about remaining discrepancies were made by the third investigator. Studies were sorted by NOS score in the result tables providing the opportunity for readers to interpret the results accordingly.

3. Results

The number of references remaining at each step of the study selection process is shown in the PRISMA flow chart in Fig. 1. The initial search of the six




Fig. 1. Flow chart for article search and selection process.

databases resulted in 2562 records. Experts from the field added 61 references, while the reference lists identified a further 15 studies to be screened, adding up to 76 extra references. After removing duplicates, 1816 studies remained for title/abstract screening. The two independent reviewers reached consensus to include 66 articles that potentially fitted the predefined PICOS criteria for full-text review. Two studies were excluded because the full-text articles appeared to be unavailable in English. Of the remaining 64 articles, 54 were excluded for a variety of other reasons (Fig. 1). Ultimately, this review included a total of ten studies. All included studies were present in the initial database search. Excluded articles are listed in appendix Table B including reasons for exclusion.

3.1. Characteristics of the included studies

All included studies were observational, and no randomised controlled trials (RCTs) were found. Of the ten studies included, seven were performed in Northern European countries and three were in Western European countries (Table 2). Three case-control studies were included, whereas the other references were all

from cohort studies. The case-control studies included 108, 198 and 110,619 cases, whereas the control groups comprised 216, 1218 and ~23,000 subjects, respectively [30–32]. The sample sizes in the cohort studies varied from 15,257 to about 4,200,000 women, although not all reported the exact sample size. Across studies, the starting age for screening was between 20 and 35 while screening was performed until age 49 to 69 with intervals ranging between two and five years. One study [31] did not report the screening interval. The follow-up time was at least five years in the cohort studies [33], with a maximum of 36 years [34]. Adherence in the cohort studies ranged from 72% to 86%, although this information was missing from three studies [33–35]. The year in which the studies were published ranged from 1979 to 2016 with most published before 1995.

3.2. Risk of bias

The risk of bias varied between studies (Table 2). Three studies [31,33,36] scored four of nine points on the NOS, four studies scored five or six points and three studies [30,32,37] scored seven, eight or nine points. Two of three studies from Western Europe were among those

Table 2

Characteristics, risk of bias and results on cervical cancer mortality of included studies, by region (based on EuroVoc) and quality score.

Region/Study	Country	Study type	Participants	Target age (years)	Screening interval (years)	Follow-up (years)	Adherence (%)	Correction for self-selection bias	NOS score ^a	RR (95% CI) for cervical cancer mortality (invited)	RR (95% CI) for cervical cancer mortality (participated)
Northern Europe [24]											
Lönnerberg S, 2013 [30]	Finland	Case control	198 cases (71 ^b) 1218 controls ^c (876 ^b)	25–69	5	N/A	N/A	Yes	9/9		0.34 (0.14–0.49)
Dugué P, 2014 [37]	Denmark	Cohort	903,439 participants 253,232 non-participants ^c	23–59	3	13	78	No	7/9		0.13 (0.11–0.15)
Bergström S, 1999 [34]	Sweden	Cohort	24,389 cases 10,655 deaths	30–49	4	26–36	86 ^d	Invited vs. non-invited	6/9	0.21 (N/A)	
Mählck C, 1994 [35]	Sweden	Cohort	~4.200.000 invited	30–49	4–5	22	86 ^d	Invited vs. non-invited	6/9	0.47 (0.28–77)	
Berget A, 1979 [48]	Denmark	Cohort	13,148 participants 2109 non-participants ^c	30–49	4–5	6–8	86	Yes	6/9	0.70 (N/A) ^e	0.16 (N/A)
Lynge E, 1989 [49]	Denmark	Cohort	N/A	20–59	2	15	72–81	Invited vs. non-invited	5/9	0.68 (0.59–0.78)	
Magnus K, 1987 [36]	Norway	Cohort	45,960 invited	25–59	2–4	24	76	Yes	4/9	0.83 (N/A)	0.59 (N/A)
Western Europe [24]											
Landy R, 2016 [32]	United Kingdom	Case control	11,619 cases ~ 23,000 controls ^c	35–64	3–5	5	N/A	No	8/9		0.08 (0.07–0.09)
Macgregor E, 1994 [31]	Scotland	Case control	108 cases (38 ^b) 216 controls ^c (157 ^b)	25–60	N/A	N/A	N/A	No	4/9		0.25 (0.12–0.48)
Ebeling K, 1986 [33]	Germany	Cohort	N/A ^c	20–64	2	5	N/A	No	4/9		0.09 (N/A)

NOS, Newcastle-Ottawa Scale; CI, confidence interval; N/A, not available; RR, relative risk (odds ratio and percent reduction are presented as a RR because they are similar because of the relative low incidence of cervical cancer) [25].

Target age: Ages targeted by the organized screening programme; Follow-up: Follow-up time after initiation of the screening programme.

^a Quality assessment made according to the Newcastle-Ottawa Scale.

^b Exposed to screening.

^c Controls were drawn from the same population as the intervention group.

^d Estimation based on Stenkvist et al. (1984), women with 2 or more smears over a ten-year period [47].

^e Not significant.

with four points. The most common criteria that affected the risk of bias assessment were a lack of information on the prevalence of CC at the start of the study and on the length of the follow-up. Furthermore, authors often failed to correct for any differences between the intervention and control groups (e.g. age) and did not specify the method by which the exposure to the intervention was measured. [Tables C.1 and C.2](#) in the appendix provide the arguments for each score on the NOS. An overview of all conflict of interest statements is provided in [appendix Table D](#).

3.3. CC mortality outcomes

All included studies reported a reduction in CC mortality ([Table 2](#)) in those attending screening compared with non-attenders ([Fig. 2a](#)) and in those invited for screening compared with non-invited women ([Fig. 2b](#)), although not all studies reported whether this reduction was found to be significant or not. In cohort studies reporting the effect of inviting a population for screening, the CC mortality reduction was between 17% and 79% in Northern Europe; no such studies were performed in other regions. In cohort studies from Northern Europe, CC mortality reduction among those participating in screening was between 41% and 84% in studies that corrected for self-selection bias and 87% in the study that did not do so. The cohort study from Western Europe did not correct for self-selection bias and reported a CC mortality reduction of 91%. In the case-control study in Northern Europe, the OR of dying from CC after participating in screening compared with non-participants, and corrected for self-selection bias, was 0.34 (95% CI: 0.14–0.49) [30]. In the two case-control studies from Western Europe, the ORs were 0.08 (95% CI: 0.07–0.09) [32] and 0.25 (95% CI: 0.12–0.48) [31], both uncorrected for self-selection bias.

4. Discussion

This systematic review shows that there is relatively little published evidence on CC mortality reduction after implementation of organised CC screening in Europe. No RCTs were reported from Europe, and there were no studies of any sort from Southern and Eastern Europe. However, in Northern Europe, two recent high-quality observational studies were reported. One showed a 51–86% CC mortality reduction after participation in organised screening, corrected for self-selection bias [30], and the other showed a 85–89% CC mortality reduction without correction for self-selection bias. In the 1990s, two large cohort studies were performed, showing a 23–72% CC mortality reduction after invitation for screening, although the target age range in the screening programmes at that time was still restricted to 30–49 years. In Western Europe, one recent high-quality study

was conducted showing a 92% CC mortality reduction without correction for self-selection bias. The other two studies from Western Europe were both conducted before 1995 and scored four points on the NOS scale. Overall, therefore, the evidence confirms that screening for CC is associated with CC mortality reduction.

This conclusion is in line with a previous review performed by Peirson et al. [38] who found an association between screening for CC and CC mortality reduction. However, Peirson et al. [38] mainly found incidence reduction studies during their search, while focussing on a single Indian RCT when assessing CC mortality reduction (RR = 0.65 [95% CI = 0.47, 0.90]). The conclusions of this trial might not be applicable to the European setting as the background risk is likely to be different and the trial assessed the effect of a single lifetime screening only. To our knowledge, no other systematic reviews have been performed on the effect of CC screening on CC mortality.

The main strength of this systematic review is that it summarises all current existing evidence on the effects of CC screening on CC mortality in Europe while also providing information on the risks of bias within those studies. The scale of the reduction in CC mortality that we found is an important reason to implement or improve a CC screening programme. The effect size of the included studies varied, which can be explained by various reasons. Differences in CC mortality reduction between an invited and an attending population will depend on attendance rates of the invited population. Within the group of attenders, differences in CC mortality reduction can be expected based on follow-up time, general background risk, demographics of the study population and the characteristics of the screening programme and screening tests [19]. Furthermore, differences in effect size can be caused by selection of any control group if there is no correction applied for any differences in background risk, and the effect size can also be influenced by differences in treatment effectiveness over time and between countries [1]. To quantify the effects of each of the parameters affecting CC mortality reduction, simulation models could be used. These simulation models can mimic the natural history of CC in a population and apply different screening scenarios to compare expected CC mortality reduction between those scenarios. Despite all the different study settings in the studies found in this systematic review, there was a clear reduction in CC mortality in all ten included studies, of which most showed a statistical significant difference. This provides robust evidence that organised CC screening is able to reduce CC mortality.

Although all included studies found reductions in CC mortality associated with CC screening, some limitations must be mentioned. First, grey literature and non-English literature were excluded. Second, the NOS used to assess the risk of bias in the eligible studies was not specifically created for assessing screening intervention




Fig. 2. (a) Reduction in cervical cancer mortality after attending screening by European region [24] and NOS score. NOS = Newcastle-Ottawa scale (i.e. a higher score is a lower risk of bias) [27]; # Uncorrected for self-selection bias; Confidence intervals are shown as error bars if they were reported in the corresponding study. Fig. 2. (b) Reduction in cervical cancer mortality after being invited for screening in Northern Europe [24] by NOS score. NOS = Newcastle-Ottawa scale (i.e. a higher score is a lower risk of bias) [27]; Confidence intervals are shown as error bars if they were reported in the corresponding study. *Estimation based on Stenkvist et al. [47], women with 2 or more smears over a ten-year period.

studies [27]. Different but important risks of bias might be present in screening intervention studies, such as the coexistence of opportunistic screening, that are not assessed by the NOS. Third, we found no RCTs, which can be considered to be the gold standard for measuring the direct effect of an intervention, although also limited in terms of the ability to generalise from trial data to the wider population [39]. CC screening was implemented in most countries before evidence from RCT's was collected. However, observational studies with a low risk of bias do provide important and useful evidence [40]. Fourth, there was lack of evidence from many countries within Europe. The lack of evidence from Southern and Eastern Europe could be because only 11% of these countries have implemented a nationwide organised screening programme, compared with 88% in Northern Europe [14,15]. Lastly, the mean publication year of the included studies was 1997. In recent decades, the quality of the screening programmes has improved, with new techniques such as thin layer cytology being introduced, improving the sensitivity of screening tests [41] and therefore the effectiveness of the programmes. However, although the more recent studies might provide the best estimate of the current CC mortality reduction, the older studies were of great value because they were the first to explore the effect of CC screening on CC mortality, setting the example for further studies.

Women can participate in screening after invitation from an organised screening programme or on their own request, that is, opportunistic screening. Organised screening programmes have many advantages over opportunistic screening as they tend to achieve higher participation rates, promote equity of access and are regularly monitored for quality assurance [11]. Furthermore, organised screening offers additional benefits by using evidence-based target ages and screening intervals chosen to reduce harms from screening, such as overdiagnosis, while optimising the benefits [6,11].

Newly implemented organised screening programmes in EU countries should be monitored for their effectiveness, and results should be made available in the public domain. This will, however, require a major investment in information systems in many countries, including linkage with clinical data systems in hospitals and primary care and with cancer registries [42].

As mentioned previously, the effect of a programme will depend on the characteristics of the screening test. Because all of the included studies used cytology as a primary test, the conclusions cannot be directly applied to other screening programmes, for instance, using a primary HPV test. HPV tests achieve higher sensitivity and specificity than cytology in identifying cervical intraepithelial neoplasia or cancer in trials [43–45]. Thus, it is reasonable to assume that CC mortality

reduction with programmes using a primary HPV test will be at least as high as the cytology-based programmes. In 2017, the Dutch-organised screening programme was the first in the world to use the HPV test as a primary screening test. Monitoring of the outcomes of this and similar programmes will provide important information on the effect of HPV screening in practice.

This systematic review focusses on the main goal of screening: reduction of CC mortality. Yet, despite all its benefits, screening can also cause harms. Healthy women who undergo screening can be anxious about the outcome, overdiagnosed or overtreated [46]. Thus, when deciding on the optimal screening strategy for a specific country, one should always weigh the benefits against the harms, a consideration that was outside the scope of this systematic review.

Our main conclusion is that even though organised screening programmes have been running for many years, there is still relatively little known about the effect of screening on CC mortality reduction. However, studies from Finland, Sweden and the United Kingdom show significant and large effects, confirming the view that organised CC screening can reduce CC mortality. These results could be used as a benchmark for other European countries using similar methods. In the absence of evidence for a specific programme or country, modelling could be used to quantify the effects of individual characteristics of screening programs and the population on CC mortality reduction for each country.

Funding

This work was supported by the EU-Framework Programme (Horizon 2020) of the European Commission [project reference 634753; PI: prof HJ de Koning, MD PhD, Erasmus MC] that funded the EU-TOPIA project of which this systematic review is part of.

Role of the funding source

The funders had no influence on the outcomes of this systematic review.

Conflict of interest

None declared.

Acknowledgements

The authors would like to thank Wichor Bramer, biomedical information specialist at the medical library of Erasmus Medical Centre (Rotterdam, the Netherlands) for his valuable help, expert inputs and solutions in the making of this systematic review.

Appendices

Collaborators

Piret Veerus
Ahti Anttila
Sirpa Heinävaara
Tytty Sarkeala
Marcell Csanádi
Janos Pitter
György Széles
Zoltán Vokó
Silvia Minozzi
Nereo Segnan
Carlo Senore

Marjolein van Ballegooijen
Inge Driesprong - de Kok
Andrea Gini
Eveline Heijnsdijk
Erik Jansen
Harry de Koning
Iris Lansdorp – Vogelaar
Nicolien van Ravesteyn
Nadine Zielonke
Urška Ivanuš
Katja Jarm
Dominika Novak Mlakar
Maja Primic-Žakelj
Martin McKee
Jennifer Priaux

Appendix Table A

Computer-assisted search code according to reference databases.

Source	Selection code
Embase	('uterine cervix tumor'/exp OR 'Papanicolaou test'/de OR 'uterine cervix cytology'/de OR (((cervix* OR cervical*) NEAR/10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR cytolog*) OR Papanicolaou OR (pap NEXT/1 (smear* OR stain* OR test*)) OR (vagina* NEAR/3 smear*)):ab,ti) AND (screening/exp OR 'early diagnosis'/de OR (screen* OR ((annual* OR periodic*) NEAR/3 examination*)) OR (early NEAR/3 (diagnos* OR detect*))) AND (mortality/de OR 'cancer mortality'/de OR (mortalit* OR (death NEXT/1 rate*)):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND [english]/lim AND [english]/lim AND (europe/exp OR (europe* OR Andorra* OR Austria* OR Balkan* OR Belg* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Montenegr* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss):ab,ti,ca,ta,cy,ad) AND ('observational study'/exp OR 'cohort analysis'/exp OR 'longitudinal study'/exp OR 'retrospective study'/exp OR 'prospective study'/exp OR 'health survey'/de OR 'health care survey'/de OR 'epidemiological data'/de OR 'case control study'/de OR 'cross-sectional study'/de OR 'correlational study'/de OR 'population research'/de OR 'family study'/de OR 'major clinical study'/de OR 'multicenter study'/de OR 'comparative study'/de OR 'follow up'/de OR 'clinical study'/de OR 'clinical article'/de OR 'clinical trial'/exp OR 'randomization'/exp OR 'intervention study'/de OR 'open study'/de OR 'community trial'/de OR 'review'/exp OR 'systematic review'/exp OR (((observation* OR epidemiolog* OR famil* OR comparativ* OR communit*) NEAR/6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/3 (stud* OR survey)) OR (health* NEAR/3 survey*) OR ((case OR cases OR match*) NEAR/3 control*) OR (cross NEXT/1 section*) OR correlation* OR multicenter* OR (multi* NEXT/1 center*) OR 'follow up' OR followup* OR clinical* OR trial OR random* OR review*):ab,ti)
Ovid Medline	("Uterine Cervical Neoplasms"/OR "Papanicolaou test"/OR "Vaginal Smears"/OR (((cervix* OR cervical*) ADJ10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR cytolog*) OR Papanicolaou OR (pap ADJ (smear* OR stain* OR test*)) OR (vagina* ADJ3 smear*)):ab,ti.) AND ("Mass Screening"/OR exp "Early Diagnosis"/OR (screen* OR ((annual* OR periodic*) ADJ3 examination*)) OR (early ADJ3 (diagnos* OR detect*))) AND (mortality/OR "cancer mortality"/OR (mortalit* OR (death ADJ rate*)):ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la. AND (exp europe/OR (europe* OR Andorra* OR Austria* OR Balkan* OR Belg* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Montenegr* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss).ab,ti,jn,cp,in.) AND ("observational study"/OR exp "Cohort Studies"/OR "Health Surveys"/OR "Epidemiologic Studies"/OR "Case-Control Studies"/OR "Cross-Sectional Studies"/OR "multicenter study"/OR "comparative study"/OR "clinical study"/OR exp "clinical trials"/OR "Random Allocation"/OR "review"/OR

(continued on next page)

Appendix Table A (continued)

Source	Selection code
Cochrane	<p>((observation* OR epidemiolog*) ADJ6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* ADJ3 (stud* OR survey)) OR (health* ADJ3 survey*) OR ((case OR cases OR match*) ADJ3 control*) OR (cross ADJ section*) OR correlation* OR multicenter* OR (multi* ADJ center*) OR "follow up" OR followup* OR clinical* OR trial OR random* OR review*).ab,ti.)</p> <p>(((cervix* OR cervical*) NEAR/10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR cytolog*)) OR Papanicolaou OR (pap NEXT/1 (smear* OR stain* OR test*)) OR (vagina* NEAR/3 smear*):ab,ti) AND ((screen* OR ((annual* OR periodic*) NEAR/3 examination*)) OR (early NEAR/3 (diagnos* OR detect*))) AND ((mortalit* OR (death NEXT/1 rate*)):ab,ti) AND ((europe* OR Andorra* OR Austria* OR Balkan* OR Belgi* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Monteneg* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss))</p>
Web of science	<p>TS=(((cervix* OR cervical*) NEAR/10 (cancer* OR neoplas* OR tumo* OR carcino* OR adenocarcin* OR cytolog*)) OR Papanicolaou OR (pap NEAR/1 (smear* OR stain* OR test*)) OR (vagina* NEAR/2 smear*)) AND ((screen* OR ((annual* OR periodic*) NEAR/2 examination*)) OR (early NEAR/2 (diagnos* OR detect*))) AND ((mortalit* OR (death NEAR/1 rate*))) AND ((europe* OR Andorra* OR Austria* OR Balkan* OR Belgi* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Monteneg* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss)) AND (((observation* OR epidemiolog* OR famil* OR comparativ* OR communit*) NEAR/5 (stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/2 (stud* OR survey)) OR (health* NEAR/2 survey*) OR ((case OR cases OR match*) NEAR/2 control*) OR (cross NEAR/1 section*) OR correlation* OR multicenter* OR (multi* NEAR/1 center*) OR "follow up" OR followup* OR clinical* OR trial OR random* OR review*)) AND DT=(article) AND la=(english)</p>
PubMed publisher	<p>("Uterine Cervical Neoplasms"[mh] OR "Papanicolaou test"[mh] OR "Vaginal Smears"[mh] OR ((cervix*[tiab] OR cervical*[tiab]) AND (cancer*[tiab] OR neoplas*[tiab] OR tumo*[tiab] OR carcino*[tiab] OR adenocarcin*[tiab] OR cytolog*[tiab])) OR Papanicolaou OR pap smear*[tiab] OR pap stain*[tiab] OR pap test*[tiab] OR vaginal smear*[tiab])) AND ("Mass Screening"[mh] OR "Early Diagnosis"[mh] OR (screen*[tiab] OR (annual*[tiab] OR periodic*[tiab]) AND examination*[tiab])) OR (early AND (diagnos*[tiab] OR detect*[tiab]))) AND (mortality[mh] OR "cancer mortality"[mh] OR (mortalit*[tiab] OR (death rate*[tiab]))) NOT (letter[pt] OR news [pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND english[la] AND english[la] AND (europe[mh] OR (europe* OR Andorra* OR Austria* OR Balkan* OR Belgi* OR Albania* OR Baltic-State* OR Bosnia* OR Herzegovina* OR Bulgaria* OR Croatia* OR Czech* OR Hungar* OR Kosovo* OR Macedonia* OR Moldova* OR Monteneg* OR Poland* OR polish* OR Belarus* OR Romania* OR Russia* OR Serbia* OR Slovakia* OR Slovenia* OR Ukraine* OR France* OR french OR German* OR Gibraltar* OR Great-Brit* OR uk OR united-kingdom* OR England* OR Scotland* OR Wales* OR welsh OR Greece* OR Ireland* OR Italy OR Italian OR Liechtenstein* OR Luxembourg* OR Monaco* OR Netherlands* OR dutch OR holland OR Portug* OR San-Marino* OR Scandinavia* OR Nordic* OR Denmark* OR danish OR Finland* OR finnish OR Iceland* OR Norwa* OR norwegian OR Sweden* OR swedish OR Spain* OR spanish OR Switzerland* OR swiss)) AND ("observational study"[pt] OR "Cohort Studies"[mh] OR "Health Surveys"[mh] OR "Epidemiologic Studies"[mh] OR "Case-Control Studies"[mh] OR "Cross-Sectional Studies"[mh] OR "multicenter study"[pt] OR "comparative study"[pt] OR "clinical study"[pt] OR "clinical trials"[pt] OR "Random Allocation"[mh] OR "review"[pt] OR (((observation*[tiab] OR epidemiolog*[tiab]) AND (stud*[tiab] OR data OR research)) OR cohort*[tiab] OR longitudinal*[tiab] OR retrospectiv*[tiab] OR prospectiv*[tiab] OR population*[tiab] OR (national*[tiab] OR survey)) OR (health*[tiab] AND survey*[tiab]) OR ((case OR cases OR match*[tiab]) AND control*[tiab]) OR (cross section*[tiab]) OR correlation*[tiab] OR multicenter*[tiab] OR (multi center*[tiab]) OR "follow up" OR followup*[tiab] OR clinical*[tiab] OR trial OR random*[tiab] OR review*[tiab])) AND publisher[sb]</p>
Google Scholar	<p>"cervix cervical cancer neoplasm tumor carcinoma adenocarcinoma cytology "pap smear stain test "vaginal smear" screening mortality "death rate" europe cohort longitudinal prospective retrospective trial epidemiological epidemiologic</p>

Appendix Table B
Characteristics of excluded studies.

Study	Reason for exclusion	Study	Reason for exclusion
Van der Aa M, 1993	The study did not provide absolute numbers of events and participants or a relative risk.	Kostova P, 2010	No group sizes reported and no relative risk.
Aareleid T, 1993	Rates before and after screening implementation. Causal relation between screening and mortality reduction not tested.	Kovács A, 2008	Study provides no mortality or incidence data
Adami H, 1994	The study did not provide absolute numbers of events or a relative risk.	Laara E, 1987	The study did not provide absolute numbers of events and participants or a relative risk.
D'Alò D, 2010	Causal relation between screening and mortality reduction not tested.	Lönnberg S, 2012	No mortality outcomes, only incidence
Andrae B, 2008	No mortality outcomes, only incidence	Louhivuori K, 1991	Causal relation between screening and mortality reduction not tested.
Anttila A, 1999	Control group receives screening.	Májek O, 2016	Follow-up <5 years.
Anttila A, 2007	Provides an overview of other studies.	Minelli L, 2007	The study did not provide absolute numbers of events and participants or a relative risk.
Anttila A, 2011	Control group receives screening.	Murphy M, 1987	The study did not provide absolute numbers of events and participants or a relative risk.
Apostol I, 2010	No baseline measurement.	Nieminen P, 1995	No number of events reported and no relative risk.
Arbyn M, 2012	Provides an overview of other studies.	Nieminen P, 1999	No mortality outcomes, only incidence
Bojar I, 2012	Presented results are on absolute reductions.	Nowakowski A, 2015	No number of events reported and no relative risk.
Castillo M, 2018	Full article not available in English.	Nygaard J, 2002	No absolute number of events. Control group receives screening.
Comber H, 2004	Causal relation between screening and mortality reduction not tested.	Parazzini F, 1990	No mortality outcomes, only incidence
Cossu A, 2014	Causal relation between screening and mortality reduction not tested.	Peto J, 2004	No population size, estimation of deaths without screening based on past. Causal relation between screening and mortality reduction not tested.
Crocetti E, 2007	No mortality outcomes, only incidence	Petterson F, 1995	No number of events reported and no relative risk.
Day N,	Provides an overview of other studies.	Quinn M, 1999	No number of events reported and no relative risk.
Ferraroni M, 1989	No mortality or incidence data provided.	Ronco G, 2005	No mortality outcomes, only incidence
Gad C, 1976	Causal relation between screening and mortality reduction not tested.	Sasieni P, 2009	No mortality outcomes, only incidence
Habbema D, 2012	Control group receives screening.	De Schryver A, 1989	Causal relation between screening and mortality reduction not tested. No relative risk.
Hakama M, 1976	Intervention group was after first negative smear.	Serraino D, 2015	No mortality outcomes, only incidence
Hakama M, 1985	Provides an overview of other studies. No group sizes reported and same data as Hakulinen 1985.	Sigurdsson K, 1989	Causal relation between screening and mortality reduction not tested. No relative risk.
Hakulinen T, 1985	Provides an overview of other studies. No group sizes reported and no relative risk.	Sigurdsson K, 1993	Causal relation between screening and mortality reduction not tested. No relative risk.
Herbert A, 1998	Trend analysis. Causal relation between screening and mortality reduction not tested.	Sigurdsson K, 1999	Causal relation between screening and mortality reduction not tested. No relative risk.
Herbert A, 2000	No group sizes reported and no relative risk.	Sigurdsson K, 2006	Causal relation between screening and mortality reduction not tested. No relative risk.
Johannesson G, 1982	Presented results do not take screening history into account. No relative risk.	Simonella L, 2013	No number of cases reported. No control group.
Karxmarek-Borowska B, 2013	Full article not available in English.	Timonen S, 1974	Letter, No number of study groups or a relative risk.
Kinney W, 2003	Study not performed in Europe (U.S.A.)	Timonen S, 1974	No number of study groups or a relative risk.
Kok I, 2011	Causal relation between screening and mortality reduction not tested.	Timonen S, 1977	The study did not provide absolute numbers of events and participants.

Appendix Table C.1
Risk of bias in Case-control studies according to Newcastle–Ottawa Scale.

Study	Selection				Comparability		Exposure			
	Case definition	Representativeness of the cases	Control selection	Control definition	Study controls for age	Any additional factors	Ascertainment	Same method for case and control	Non-Response rate	Final result
Landy R, 2016	Yes, but no actual deaths were counted, calculated number of deaths based on survival data were used.	Consecutive series of cases. All women who had cervical cancer between April 2007 and March 2013. (*)	Community controls. “All women registered with an NHS GP who did not have cervical cancer at the time of diagnosis were eligible as a control.” (*)	No history of disease. “All women registered with an NHS GP who did not have cervical cancer at the time of diagnosis were eligible as a control.” (*)	Controls were matched for age. (*)	Controls were matched for area of residence. (*)	Secure record. Screening data were abstracted from routinely recorded cervical cytology records held on the Cervical Screening call/recall system which include all NHS smears taken in the UK. (*)	Yes. (*)	Same rate for both groups. Records include all NHS smears taken in the UK. (*)	8/9
Lönnberg S, 2013	Record linkage with the cancer register. Cancer register has 99.5% histologically verified cases [29]. (*)	Consecutive series of cases. All registered cervical cancer deaths from the years 2000–2009. (*)	Community controls, drawn from the population register. (*)	No history of disease. “Only women alive and not diagnosed with cervical cancer at the time of diagnosis of the case were eligible as controls.” (*)	Cases and controls were matched for birth year and month. (*)	Study corrected for self-selection bias. (*)	Secure record. Study objects were linked to the screening register database. (*)	Yes. (*)	Same rate for both groups. Thirty-nine cases excluded for other reasons. (*)	9/9
Macgregor E, 1994	Yes, the records of the cases were obtained from hospital records and the cytopathology database. (*)	Not stated.	No description.	No history of disease. Controls have had a negative smear test result at the date of presentation of the case. (*)	Controls were matched for age. (*)	No.	Secure record. Screening history was assessed using the cytopathology database. (*)	No statement.	Non-respondents described.	4/9

(*) The presence of this symbol means the study fitted the selected criteria and it was accounted in the final result. NHS, National Health Service; GP, general practitioner.

Appendix Table C.2

Risk of bias in cohort studies according to Newcastle-Ottawa Scale.

Study	Selection				Comparability		Outcome			
	Representativeness of the exposed cohort	Selection of the non-exposed	Ascertainment of exposure	Absence of interest	Study controls for age	Any additional factors	Assessment of outcome	Follow-up Length (>8 years)	Adequacy of follow-up	Final result
Berget A, 1979	Truly representative of the average Danish female population between 30 and 49 years old as all were invited for screening. (*)	Drawn from the same community as the exposed cohort. Not attending women. (*)	Invitation lists and meeting lists were used to measure invitation and attendance. (*)	Yes. Women with prior cervical lesion or hysterectomy were excluded. (*)	No. Quote: "The size of the study population does not allow correction for this."	No.	Record linkage using death certificates and data from the Danish Cancer Registry. (*)	No. 6–8 years.	Yes. Only 0.64% were not identified and excluded. Emigrated women were followed and/ well described. (*)	6/9
Bergström S, 1999	Truly representative of the average Swedish female population between 30 and 49 years old as all were invited for screening. (*)	Drawn from the same community as the population in the years before implementation of screening. (*)	Amount of smears reported, but the method of ascertainment is not described.	No.	Standardised for age to the Swedish census population in 1970. (*)	Study corrected for period and cohort. (*)	Record linkage using the Swedish Cancer Register and the Swedish Cause of Death Register at Statistics Sweden. (*)	Yes. 26–36 years. (*)	No statement.	6/9
Dugué P, 2014	Truly representative of the average Danish population between 23 and 51 years old, as all had the possibility to participate in two rounds of screening. (*)	Drawn from the same community as the exposed cohort. Not attending women. (*)	Secure record. Data on samples were retrieved from the Danish Pathology Data Bank, the National Health Service Register and the National Patient Register. (*)	No.	Yes. (*)	No.	Record linkage between the Danish Civil Registration System and the Danish Cause of Death Register using personal ID numbers. (*)	Yes. 13 years. (*)	Small number lost. Unlikely to introduce bias. (*)	7/9
Ebeling K, 1986	Somewhat representative of the average Berlin women between 20 and 64 years old. (*)	Drawn from the same community as the exposed cohort. Not attending women. (*)	No description of method. Screening histories of all patients with cervical cancer were carefully monitored.	No.	No correction for age.	No.	Smears were re-examined and records of gynaecologists and gynaecological hospitals were checked. (*)	Yes. 10 years. (*)	No statement.	4/9
Lynge E, 1989	Somewhat representative of the average Danish female population between 30 and 59 years old as some counties were excluded. (*)	Drawn from a different source. Different areas, with low smear-taking activity	No description of method. Authors only mention that data are available.	No.	The study corrected for 6 5-year age groups using a Poisson model. (*)	The study corrected for 4 5-year calender periods and 19 counties. (*)	Record linkage with death certificates and the Danish Cancer Registry. (*)	Yes ~15 years. (*)	No statement.	5/9
Magnus K, 1987	Truly representative of the average female population in the county of Ostfold between 25 and 59 years old as all were invited for screening. (*)	Drawn from a different source. Female population of neighbouring counties. Rates are only used from 1963 to 1967.	Secure record. Screening history by national identification number. (*)	No.	No.	No.	Record linkage between the Cancer Registry and the Central Bureau of Statistics. (*)	Yes. 24 years. (*)	No statement.	4/9
Mählck C, 1994	Truly representative of the average Swedish female population between 30 and 49 years old as all were invited for screening. (*)	Drawn from the same community as the exposed cohort. Same population in the years before implementation of screening. (*)	No description.	No.	Yes, with the population of Sweden 1970 as a reference. (*)	Study controls for period and county. (*)	Record linkage between the Population Register and the Cause of Death Register at the Swedish Central Bureau of Statistics. (*)	Yes. 22 years. (*)	No statement.	6/9

(*) The presence of this symbol means the study fitted the selected criteria and it was accounted in the final result.

Appendix Table D

Conflict of interest and/or statements of all included studies.

Study	Conflict of interest and/or funding statement
Berget A, 1979	No statement.
Bergström S, 1999	No statement.
Dugué P, 2014	Pierre-Antoine Dugué declares no potential conflict of interest. Elsebeth Lyngø and Matejka Rebolj are currently undertaking a comparative study of new-generation HPV tests, involving collaboration with Roche Diagnostics, Genomica, Qiagen and Genprobe. Elsebeth Lyngø has served as unpaid scientific advisor to Genprobe and Norchip. Matejka Rebolj's employer received honoraria for lectures from Qiagen on her behalf. Concerning the present paper, there has been no collaboration with, or support from any of the companies. Grant sponsor: University of Copenhagen, Danish Strategic Research Council.
Ebeling K, 1986	No statement.
Landy R, 2016	The authors declare no conflict of interest. This work was supported by Cancer Research UK (A16892 to P.S.).
Lönnberg S, 2013	Grant sponsors: Finnish Cancer Organisations; European Union Seventh Framework Programme contract EUROCOURSE-Europe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in research. Co-funding was provided by the European Union Public Health Programme (Project no. 2006322, European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines [ECCG]).
Lyngø E, 1989	The costs of publication of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked <i>advertisement</i> in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Macgregor E, 1994	No statement.
Magnus K, 1987	No statement.
Mählek C, 1994	This investigation was supported by Lions' Research Foundation, University of Umeå and by Swedish Cancer Society (RmC), project no. 1759-B89-03XB.

Appendix E. Reference list of excluded articles

- [1] Van Der Aa MA, Pukkala E, Coebergh JWW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and The Netherlands. *Int J Cancer*. 2008;122:1854-1858.
- [2] Aareleid T, Pukkala E, Thomson H, Hakama M. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population. *EUR J CANCER PART A GEN TOP*. 1993;29:745-749.
- [3] Adami HO, Ponten J, Sørensen P, Bergström R, Gustafsson L, Friberg LG. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening: 1960-1984. *Cancer*. 1994;73:140-147.
- [4] D'Alò D, Stracci F, Cassetti T, Scheibel M, Pascucci C, La Rosa F. Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978-2005. *Eur J Gynaecol Oncol*. 2010;31:174-180.
- [5] Andrae B, Kemetli L, Sørensen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *J Natl Cancer Inst*. 2008;100:622-629.
- [6] Anttila A, Nieminen P. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. *Coll Antropol*. 2007;31:17-22.
- [7] Anttila A, Pokhrel A, Kotaniemi-Talonen L, Hakama M, Malila N, Nieminen P. Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study. *Int J Cancer*. 2011;128:1204-1212.
- [8] Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. *Int J Cancer*. 1999;83:59-65.
- [9] Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, et al. Cervical cancer assessment in Romania under EUROCHIP-2. *Tumori*. 2010;96:545-552.
- [10] Arbyn M, Weiderpass E, Capocaccia R. Effect of screening on deaths from cervical cancer in Sweden. *Br Med J*. 2012;344.
- [11] Bojar I, Cvejić R, GŁowacka MD, Koprowicz A, Humeniuk E, Owoc A. Morbidity and mortality due to cervical cancer in Poland after introduction of the national programme for control of cancerous diseases. *Ann Agric Environ Med*. 2012;19:680-685.
- [12] Castillo M, Astudillo A, Clavero O, Velasco J, Ibanez R, de Sanjose S. [Evaluation of mortality after the analysis of the screening history in women diagnosed with infiltrating cervical cancer] Evaluacion de fallos tras el analisis de la historia de cribado en mujeres diagnosticadas de cancer infiltrante de cuello uterino. *Atención Primaria*. 2018;50:151-158.
- [13] Comber H, Gavin A. Recent trends in cervical cancer mortality in Britain and Ireland: the case for population-based cervical cancer screening. *Br J Canc*. 2004;91:1902-1904.
- [14] Cossu A, Capobianco G, Budroni M, Surico D, Cesaraccio R, Tanda F, et al. Report on incidence and mortality trends of cervical cancer in Northern Sardinia, Italy. *Eur J Gynaecol Oncol*. 2014;35:544-547.
- [15] Crocetti E, Battisti L, Betta A, Palma PD, Paci E, Piffer S, et al. The cytological screening turned out effective also for adenocarcinoma: a population-based case-control study in Trento, Italy. *Eur J Cancer Prev*. 2007;16:564-567.
- [16] Day NE. Effect of cervical cancer screening in Scandinavia. *Obstet Gynecol*. 1984;63:714-718.

- [17] Ferraroni M, La Vecchia C, Pagano R, Negri E, Parazzini F, Decarli A. Pattern of cervical screening utilization in Italy. *Tumori*. 1989;75:420-422.
- [18] Gad C. Cervical carcinoma in Frederiksberg borough: the influence of population screening on mortality. *Dan Med Bull*. 1976;23:295-299.
- [19] Habbema D, De Kok IMCM, Brown ML. Cervical cancer screening in the United States and The Netherlands: a tale of two countries. *Milbank Q*. 2012;90:5-37.
- [20] Hakama M. Effect of population screening for carcinoma of the uterine cervix in Finland. *Maturitas*. 1985;7:3-10.
- [21] Hakama M, Rasanen-Virtanen U. Effect of a mass screening program on the risk of cervical cancer. *Am J Epidemiol*. 1976;103:512-517.
- [22] Hakulinen T, Hakama M. The effect of screening on the incidence and mortality of cervical cancer in Finland. *NOWOTWORY*. 1985;35:290-296.
- [23] Herbert A. Cervical screening in England and Wales: its effect has been underestimated. *Cytopathology*. 2000;11:471-479.
- [24] Herbert A, Bryant TN, Campbell MJ, Smith J. Investigation of the effect of occult invasive cancer on progress towards successful cervical screening. *J Med Screen*. 1998;5:92-98.
- [25] Johannesson G, Geirsson G, Day N, Tulinius H. Screening for cancer of the uterine cervix in Iceland 1965-1978. *Acta Obstet Gynecol Scand*. 1982;61:199-203.
- [26] Karczmarek-Borowska B, Gradalska-Lampart M. Cervical cancer incidence and mortality rates including the screening program results in the Podkarpackie Region between 1999-2010. *Ginekol Pol*. 2013;84:930-937.
- [27] Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenocarcinoma carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. *Acta Cytol*. 2003;47:167-171.
- [28] De Kok IMCM, Van Der Aa MA, Van Ballegooijen M, Siesling S, Karim-Kos HE, Van Kemenade FJ, et al. Trends in cervical cancer in The Netherlands until 2007: has the bottom been reached? *Int J Cancer*. 2011;128:2174-2181.
- [29] Kostova P, Zlatkov V. Is cervical cancer screening necessary or the "Paradox" example of Bulgaria. *J B U ON*. 2010;15:556-560.
- [30] Kovács A, Döbrossy L, Budai A, Boncz I, Cornides Á. Cervical screening in Hungary: why does the "English model" work but the "Hungarian model" does not? *Eur J Gynaecol Oncol*. 2008;29:5-9.
- [31] Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. *LANCET (N AM ED)*. 1987;1:1247-1249.
- [32] Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer Epidemiol Biomark Prev*. 2012;21:1354-1361.
- [33] Louhivuori K. Effect of a mass screening program on the risk of cervical cancer. *Cancer Detect Prev*. 1991;15:471-475.
- [34] Májek O, Dušková J, Dvořák V, Beková A, Klimeš D, Blaha M, et al. Performance indicators in a newly established organized cervical screening programme: registry-based analysis in the Czech Republic. *Eur J Cancer Prev*. 2016.
- [35] Minelli L, Stracci F, Cassetti T, Scheibel M, Sapia IE, La Rosa F. Epidemiological overview on the effectiveness of mass screening for female cancer in Umbria, Italy. *Eur J Gynaecol Oncol*. 2007;28:297-301.
- [36] Murphy MFG, Campbell MJ, Goldblatt PO. Twenty years' screening for cancer of the uterine cervix in Great Britain, 1964-84; Further evidence for its ineffectiveness. *J Epidemiol Community Health*. 1988;42:49-53.
- [37] Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous pap-smear screening for cervical cancer: a case-control study. *Int J Cancer*. 1999;83:55-58.
- [38] Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. *Obstet Gynecol*. 1995;85:1017-1021.
- [39] Nowakowski A, Cybulski M, Śliwczyński A, Chil A, Teter Z, Seroczyński P, et al. The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. *BMC Canc*. 2015:1-11.
- [40] Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. *J Med Screen*. 2002;9:86-91.
- [41] Parazzini F, Negri E, La Vecchia C, Bocciolone L. Screening practices and invasive cervical cancer risk in different age strata. *Gynecol Oncol*. 1990;38:76-80.
- [42] Peto PJ, Gilham PC, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. *Lancet*. 2004;364:249-256.
- [43] Pettersson F, Bjorkholm E, Naslund I. Evaluation of screening for cervical cancer in Sweden: trends in incidence and mortality 1958-1980. *Int J Epidemiol*. 1985;14:521-527.
- [44] Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. *Br Med J*. 1999;318:904-908.
- [45] Ronco G, Pilutti S, Patriarca S, Montanari G, Ghiringhello B, Volante R, et al. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. *Br J Canc*. 2005;93:376-378.
- [46] Sasieni P, Castanon A, Cuzick J, Snow J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *Br Med J*. 2009;339:328.
- [47] De Schryver A. Does screening for cervical cancer affect incidence and mortality trends? The Belgian experience. *Eur J Cancer Clin Oncol*. 1989;25:395-399.
- [48] Serraino D, Gini A, Taborelli M, Ronco G, Giorgi-Rossi P, Zappa M, et al. Changes in cervical cancer incidence following the introduction of organized screening in Italy. *Prev Med*. 2015;75:56-63.
- [49] Sigurdsson K. Effect of organized screening on the risk of cervical cancer, evaluation of screening activity in Iceland, 1964-1991. *Int J Cancer*. 1993;54:563-570.

- [50] Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. *Acta Obstet Gynecol Scand.* 1999;78:478–485.
- [51] Sigurdsson K, Adalsteinsson S, Tulinius H, Ragnarsson J. The value of screening as an approach to cervical cancer control in Iceland, 1964–1986. *Int J Cancer.* 1989;43:1–5.
- [52] Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964–2002: a study on trends in incidence and mortality and the effect of risk factors. *Acta Obstet Gynecol Scand.* 2006;85:343–349.
- [53] Simonella L, Canfell K. The impact of a two-versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. *Cancer Causes Control.* 2013;24:1727–1736.
- [54] Timonen S, Nieminen U, Kauraniemi T. Mass screening for cervical carcinoma in Finland: organization and effect on morbidity and mortality. *Ann Chir Gynaecol.* 1974;63:104–112.
- [55] Timonen S, Nieminen U, Kauraniemi T. Cervical screening. *LANCET (N AM ED).* 1974;1:401–402.
- [56] Timonen S, Pyorala T. Cervical cancer. Mass screening, incidence and mortality in Finland. *Acta Obstet Gynecol Scand.* 1977;56:13–19.
- [11] Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. *Eur J Cancer* 2009;45:2671–8.
- [12] GLOBOCAN. Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012: IARC.
- [13] Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, et al. Status of implementation and organization of cancer screening in the European Union Member States-Summary results from the second European screening report. *Int J Cancer* 2018;142:44–56.
- [14] Elfstrom KM, Arnheim-Dahlstrom L, von Karsa L, Dillner J. Cervical cancer screening in Europe: quality assurance and organisation of programmes. *Eur J Cancer* 2015;51:950–68.
- [15] Ponti A, Anttila A, Ronco G, Senore C. Cancer Screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening. IARC Sci Publ; 2017. 2017.
- [16] Council of the European Union. Council recommendation of 2 December 2003 on cancer screening. *Official Journal of the European Union* 2003;327:34–8.
- [17] Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Second edition—summary document. *Ann Oncol* 2010; 21:448–58.
- [18] de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch micro-simulation model. *BMJ* 2012;344. e670.
- [19] van Ballegooijen M, van den Akker-van Marle E, Patnick J, Lyng E, Arbyn M, Anttila A, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. *Eur J Cancer* 2000;36:2177–88.
- [20] Zielonke N, Gini A, Jansen E, Bramer W. Evidence for cancer specific and all-cause mortality reduction due to screening for breast, cervical and colorectal cancer: a systematic review. PROSPERO 2016. Available at: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=42433. CRD42016042433 2016.
- [21] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6. e1000097.
- [22] IARC. In: IARC Handbook of cancer prevention, vol. 15. Breast Cancer Screening; 2016.
- [23] Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012;9. e1001352.
- [24] Multilingual Thesaurus of the European union (EUROVOC). Available at: <https://op.europa.eu/en/web/eu-vocabularies/th-concept-scheme/-/resource/eurovoc/100277?target=Browse>. Last Accessed: 8 November 2019.
- [25] Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *J Am Med Assoc* 1998;280:1690–1.
- [26] Persoskie A, Ferrer RA. A most odd ratio:: interpreting and describing odds ratios. *Am J Prev Med* 2017;52:224–8.
- [27] Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
- [28] Anttila A, Lonnberg S, Ponti A, Suonio E, Villain P, Coebergh JW, et al. Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries. *Eur J Cancer* 2015; 51:241–51.

References

[1] Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer Epidemiol Biomark Prev* 2012;21:1354–61.

[2] Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *J Natl Cancer Inst* 2008;100:622–9.

[3] Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous pap-smear screening for cervical cancer: a case-control study. *Int J Cancer* 1999;83:55–8.

[4] Serraino D, Gini A, Taborrelli M, Ronco G, Giorgi-Rossi P, Zappa M, et al. Changes in cervical cancer incidence following the introduction of organized screening in Italy. *Prev Med* 2015;75: 56–63.

[5] Ronco G, Pilutti S, Patriarca S, Montanari G, Ghiringhello B, Volante R, et al. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992–98. *Br J Canc* 2005;93:376–8.

[6] Sasieni P, Castanon A, Cuzick J, Snow J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *Br Med J* 2009;339:328.

[7] Tierney B, Westin SN, Schlumbrecht MP, Ramirez PT. Early cervical neoplasia: advances in screening and treatment modalities. *Clin Adv Hematol Oncol* 2010;8:547–55.

[8] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA A Cancer J Clin* 2011;61:69–90.

[9] Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. *BMJ* 2012;344. e900.

[10] Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, et al. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study. *Lancet Oncol* 2016; 17:1445–52.

- [29] IARC. Cancer incidence in five continents.
- [30] Lönnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit of the Finnish cervical cancer screening program. *Int J Cancer* 2013;132:2134–40.
- [31] Macgregor JE, Campbell MK, Mann EMF, Swanson KY. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. *Br Med J* 1994;308:1407–11.
- [32] Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. *Br J Canc* 2016;115:1140–6.
- [33] Ebeling K, Nischan P. Organization and results of cervical cancer screening in the German Democratic Republic. *IARC Sci Publ*; 1986. p. 251–66.
- [34] Bergström R, Sparén P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. *Br J Canc* 1999; 81:159–66.
- [35] Mählck CG. Pap smear screening and changes in cervical cancer mortality in Sweden. *Int J Gynecol Obstet* 1994;44:267–72.
- [36] Magnus K, Langmark F, Andersen A. Mass screening for cervical cancer in Ostfold county of Norway 1959-77. *Int J Cancer* 1987; 39:311–6.
- [37] Dugué PA, Lynge E, Rebolj M. Mortality of non-participants in cervical screening: register-based cohort study. *Int J Cancer* 2014; 134:2674–82.
- [38] Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. *Syst Rev* 2013;2:35.
- [39] Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. *J Health Serv Res Policy* 1999;4: 112–21.
- [40] Castillo RC, Scharfstein DO, MacKenzie EJ. Observational studies in the era of randomized trials: finding the balance. *J Bone Joint Surg Am* 2012;94(Suppl 1):112–7.
- [41] Rozemeijer K, Naber SK, Penning C, Overbeek LI, Looman CW, de Kok IM, et al. Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. *BMJ* 2017;356. j504.
- [42] Capocaccia R, Martina L, Inghelmann R, Crocetti E, De Lisi V, Falcini F, et al. A method to estimate mortality trends when death certificates are imprecisely coded: an application to cervical cancer in Italy. *Int J Cancer* 2009;124:1200–5.
- [43] Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkman NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *Lancet Oncol* 2012;13:78–88.
- [44] Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *Eur J Cancer* 2011;47: 864–71.
- [45] Isidean SD, Mayrand MH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial. *Int J Cancer* 2016;139:2456–66.
- [46] Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, MCMdK I, et al. Harms of cervical cancer screening in the United States and The Netherlands. *Int J Cancer* 2017;140:1215–22.
- [47] Stenkvist B, Bergstrom R, Eklund G, Fox CH. Papanicolaou smear screening and cervical cancer. What can you expect? *J Am Med Assoc* 1984;252:1423–6.
- [48] Berget A. Influence of population screening on morbidity and mortality of cancer of the uterine cervix in Maribo Amt. *Dan Med Bull* 1979;26:98–100.
- [49] Lynge E, Madsen M, Engholm G. Effect of organized screening on incidence and mortality of cervical cancer in Denmark. *Cancer Res* 1989;49:2157–60.